RSS feed

Publications (original articles or review articles) published in 2024 from OUS - Department of Infectious Diseases

17 publications found

Alonso-Rodríguez N, Vianello E, van Veen S, Jenum S, Tonby K, van Riessen R, Lai X, Mortensen R, Ottenhoff THM, Dyrhol-Riise AM (2024)
Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy
Front Immunol, 15, 1350593
DOI 10.3389/fimmu.2024.1350593, PubMed 38433842

Barratt-Due A, Pettersen K, Børresdatter-Dahl T, Holter JC, Grønli RH, Dyrhol-Riise AM, Lerum TV, Holten AR, Tonby K, Trøseid M, Skjønsberg OH, Granerud BK, Heggelund L, Kildal AB, Schjalm C, Aaløkken TM, Aukrust P, Ueland T, Mollnes TE, Halvorsen B, NOR‐Solidarity study groupThe Norwegian SARS‐CoV‐2 study group (2024)
Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients
J Intern Med, 296 (1), 80-92
DOI 10.1111/joim.13783, PubMed 38539241

Dhariwal A, Rajar P, Salvadori G, Åmdal HA, Berild D, Saugstad OD, Fugelseth D, Greisen G, Dahle U, Haaland K, Petersen FC (2024)
Prolonged hospitalization signature and early antibiotic effects on the nasopharyngeal resistome in preterm infants
Nat Commun, 15 (1), 6024
DOI 10.1038/s41467-024-50433-7, PubMed 39019886

Fostervold A, Raffelsberger N, Hetland MAK, Bakksjø R, Bernhoff E, Samuelsen Ø, Sundsfjord A, Afset JE, Berntsen CF, Bævre-Jensen R, Ebbesen MH, Gammelsrud KW, Guleng AD, Handal N, Jakovljev A, Johal SK, Marvik Å, Natvik A, Sandnes RA, Tofteland S, Bjørnholt JV, Löhr IH, Assoc. on behalf of The Norwegian Study Group on Klebsiella pneumoniae (2024)
Risk of death in Klebsiella pneumoniae bloodstream infections is associated with specific phylogenetic lineages
J Infect, 88 (5), 106155
DOI 10.1016/j.jinf.2024.106155, PubMed 38574775

Grønmo MM, Møller-Stray J, Akselsen PE, Lindemann PC, Fostervold A, Knudsen CV, Knudsen PK, Lindbæk M, Tonby K, Sundsfjord A (2024)
Gentamicin should remain part of the empirical sepsis regimen for adults
Tidsskr Nor Laegeforen, 144 (3)
DOI 10.4045/tidsskr.23.0659, PubMed 38415563

Helset E, Cheng V, Sporsem H, Thorstensen C, Nordøy I, Gammelsrud KW, Hanssen G, Ponzi E, Lipman J, von der Lippe E (2024)
Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study
Acta Anaesthesiol Scand, 68 (4), 502-511
DOI 10.1111/aas.14376, PubMed 38286568

Hoel H, Dahl TB, Yang K, Skeie LG, Michelsen AE, Ueland T, Damås JK, Dyrhol-Riise AM, Fevang B, Yndestad A, Aukrust P, Trøseid M, Sandanger Ø (2024)
Chronic HIV Infection Increases Monocyte NLRP3 Inflammasome-Dependent IL-1α and IL-1β Release
Int J Mol Sci, 25 (13)
DOI 10.3390/ijms25137141, PubMed 39000248

Johannessen A, Reikvam DH, Aleman S, Berhe N, Weis N, Desalegn H, Stenstad T, Heggelund L, Samuelsen E, Karlsen LN, Lindahl K, Pettersen FO, Iversen J, Kleppa E, Bollerup S, Winckelmann AA, Brugger-Synnes P, Simonsen HE, Svendsen J, Kran AB, Holmberg M, Olsen IC, Rueegg CS, Dalgard O (2024)
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B
Aliment Pharmacol Ther, 60 (4), 434-445
DOI 10.1111/apt.18147, PubMed 38970293

Kjeseth T, Line PD, Khan A, Solheim JM, Bjørk IG, Sundal J, Jensenius M, Yaqub S (2024)
Ex-situ liver resection for complex Echinococcus multilocularis infection: a case report
J Surg Case Rep, 2024 (6), rjae410
DOI 10.1093/jscr/rjae410, PubMed 38868544

Kraef C, Singh S, Fursa O, Abutidze A, Rukhadze N, Mulabdic V, Yancheva N, Mehmeti M, Balayan T, Harxhi A, Trajanovska J, Mackintosh C, Duvivier C, Beniowski M, Jilich D, Reikvam DH, Tau L, Podlekareva D, Ryom L, Peters L, Kowalska J, Kirk O, EuroSIDA Study Group (2024)
Differences in integrated assessment and management of non-communicable diseases (NCDs) for people with HIV across the WHO European region
HIV Med, 25 (6), 700-710
DOI 10.1111/hiv.13619, PubMed 38361216

Malme KB, Stene-Johansen K, Klundby I, Backe Ø, Foshaug T, Greve MH, Pihl CM, Finbråten AK, Dalgard O, Midgard H (2024)
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
Viruses, 16 (6)
DOI 10.3390/v16060858, PubMed 38932151

Martinez SG, Mbabazi PS, Sebitloane MH, Vwalika B, Mocumbi S, Galaphaththi-Arachchige HN, Holmen SD, Randrianasolo B, Roald B, Olowookorun F, Hyera F, Mabote S, Nemungadi TG, Ngcobo TV, Furumele T, Ndhlovu PD, Gerdes MW, Gundersen SG, Mkhize-Kwitshana ZL, Taylor M, Mhlanga REE, Kjetland EF (2024)
The WHO atlas for female-genital schistosomiasis: Co-design of a practicable diagnostic guide, digital support and training
PLOS Glob Public Health, 4 (3), e0002249
DOI 10.1371/journal.pgph.0002249, PubMed 38498490

Midgard H, Malme KB, Pihl CM, Berg-Pedersen RM, Tanum L, Klundby I, Haug A, Tveter I, Bjørnestad R, Olsen IC, Finbråten AK, Dalgard O (2024)
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203

Murphy SL, Balzer NR, Ranheim T, Sagen EL, Huse C, Bjerkeli V, Michelsen AE, Finbråten AK, Heggelund L, Dyrhol-Riise AM, Tveita A, Holten AR, Trøseid M, Ueland T, Ulas T, Aukrust P, Barratt-Due A, Halvorsen B, Dahl TB (2024)
Extracellular matrix remodelling pathway in peripheral blood mononuclear cells from severe COVID-19 patients: an explorative study
Front Immunol, 15, 1379570
DOI 10.3389/fimmu.2024.1379570, PubMed 38957465

Nemungadi TG, Kleppa E, Galappaththi-Arachchige HN, Pillay P, Gundersen SG, Vennervald BJ, Ndhlovu PD, Taylor M, Naidoo S, Kjetland EF (2024)
Predictors for participation in mass-treatment and female genital schistosomiasis re-investigation, and the effect of praziquantel treatment in South African adolescents
PLoS Negl Trop Dis, 18 (3), e0011798
DOI 10.1371/journal.pntd.0011798, PubMed 38536861

Nore KG, Louet C, Bugge M, Gidon A, Jørgensen MJ, Jenum S, Dyrhol-Riise AM, Tonby K, Flo TH (2024)
The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth
J Infect Dis, 229 (3), 888-897
DOI 10.1093/infdis/jiad390, PubMed 37721470

Viermyr HK, Halvorsen B, Sagen EL, Michelsen AE, Barrat-Due A, Kåsine T, Nezvalova-Henriksen K, Dyrhol-Riise AM, Nor‐Solidarity Consortium, Lerum TV, Müller F, Tonby K, Tveita A, Aukrust P, Trøseid M, Ueland T, Dahl TB (2024)
High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial
J Intern Med (in press)
DOI 10.1111/joim.13820, PubMed 39011800